Significance of Oncotype DX 21-Gene Test and Expression of Long Non-Coding RNA MALAT1 in Early and Estrogen Receptor-Positive Breast Cancer Patients

Figures & data

Table 1 MALAT1 Expression in Different Subgroups of Breast Cancer Patients

	N	MALAT1	Z	P value
Age
≤50	45	2.918±2.671	−1.538	0.124
>50	31	3.101±1.497
Tumor stage
pT1	50	2.885±2.071	−0.296	0.728
pT2	26	3.199±2.608
Lymph nodes
N0	67	2.952±2.285	−0.876	0.381
N+	9	3.293±2.129
Disease grade
II	44	2.782±2.209	3.054	0.217
III	19	3.939±2.650
unknown	13	2.338±1.338
Ki-67 expression
<14%	28	2.513±1.829	−1.131	0.258
≥14%	48	3.273±2.446
PR status
PR+	70	2.990±2.257	−0.193	0.847
PR-	6	3.018±2.468

Figure 1 The expression of MALAT1 in normal and tumor tissues in breast cancer patients. Total RNA was extracted from tumor and para-tumor samples of all breast cancer patients. The RNA was reversely transcribed into cDNA, as template to amplify MALAT1 by quantitative real-time PCR.

Table 2 Association Between the RS of the Oncotype DX 21-Gene Test and Breast Cancer Clinical Characteristics

	N	Old Criteria					New Criteria
		L	M	H	Z	P value	L	M	H	Z	P value
Age
≤50	45	25	12	8	−0.165	0.869	8	25	12	−1.528	0.127
>50	31	15	16	0			6	23	2
Tumor stage
pT1	50	28	18	4	−0.977	0.328	10	36	4	−2.374	0.018
pT2	26	12	10	4			4	12	10
Lymph nodes
N0	67	35	24	8	−0.466	0.641	12	41	14	−1.162	0.245
N+	9	5	4	0			2	7	0
Grade
II	44	24	18	2	7.628	0.022	12	24	8	2.362	0.307
III	19	8	7	4			2	13	4
unknown	13	8	3	2			0	11	2
Ki-67
<14%	28	20	8	0	−2.788	0.005	10	18	0	−3.892	<0.001
≥14%	48	20	20	8			4	30	14
PR
PR+	70	36	26	8	−0.860	0.390	14	42	14	0	1.000
PR-	6	4	2	0			0	6	0

Table 3 Association Between the RS of the Oncotype DX 21-Gene Test and lncRNA MALAT1 Expression

	RS	N	MALAT1 lncRNA Expression (x±s)	Z	P value
Old RS criteria	L	40	2.286 ± 2.012	10.349	0.006
	M	28	3.576 ± 2.111
	H	8	4.484 ± 2.840
New RS criteria	L	14	2.045 ± 1.632	3.273	0.195
	M	48	3.090 ± 2.290
	H	14	3.604 ± 2.520